Page last updated: 2024-11-07

aldosterone and ADPKD

aldosterone has been researched along with ADPKD in 7 studies

Research Excerpts

ExcerptRelevanceReference
" To study the function and regulation of the aquaporin-2 water channel (AQP2) and the epithelial sodium channel (ENaC) in autosomal dominant polycystic kidney disease (ADPKD), we measured urinary excretion of AQP2 (u-AQP2), the β-subunit of ENaC (u-ENaC(β)), cAMP (u-cAMP), and prostaglandin E(2) (u-PGE(2)); free water clearance (C(H2O)); fractional sodium excretion (FE(Na)); and plasma vasopressin (p-AVP), renin (p-Renin), angiotensin II (p-ANG II), aldosterone (p-Aldo), and atrial and brain natriuretic peptide (p-ANP, p-BNP) in patients with ADPKD and healthy controls during 24-h urine collection and after hypertonic saline infusion during high sodium intake (HS; 300 mmol sodium/day) and low sodium intake (LS; 30 mmol sodium/day)."5.16Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion. ( Bech, JN; Graffe, CC; Lauridsen, TG; Pedersen, EB, 2012)
"Eight borderline hypertensive ADPKD patients with (near) normal renal function and seven matched healthy control subjects were investigated at three levels of daily dietary sodium intake: 150, 50 and 450 mmol."1.29Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion. ( Barendregt, JN; Chang, PC; Florijn, KW; Muizert, Y, 1995)
"We studied young adults with autosomal dominant polycystic kidney disease (ADPKD) to determine the characteristics that precede renal impairment."1.28Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. ( Briggs, JD; Davies, DL; Dominiczak, AF; Fraser, R; Harrap, SB; Macnicol, AM; Watson, ML; Wright, AF, 1991)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (57.14)18.2507
2000's0 (0.00)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Malmberg, MH1
Mose, FH1
Pedersen, EB2
Bech, JN2
Torres, VE1
Abebe, KZ1
Chapman, AB2
Schrier, RW1
Braun, WE1
Steinman, TI1
Winklhofer, FT1
Brosnahan, G1
Czarnecki, PG1
Hogan, MC1
Miskulin, DC1
Rahbari-Oskoui, FF1
Grantham, JJ1
Harris, PC1
Flessner, MF1
Moore, CG1
Perrone, RD1
Graffe, CC1
Lauridsen, TG1
Barendregt, JN1
Florijn, KW1
Muizert, Y1
Chang, PC1
Gabow, PA1
Cerasola, G1
Li Vecchi, M1
Mulé, G1
Cottone, S1
Mangano, MT1
Andronico, G1
Contomo, A1
Parrino, IA1
Renda, F1
Pavone, G1
Scialabba, A1
Harrap, SB1
Davies, DL1
Macnicol, AM1
Dominiczak, AF1
Fraser, R1
Wright, AF1
Watson, ML1
Briggs, JD1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) or Other Cause of Chronic Renal Disease Compared to Healthy Volunteers[NCT04363554]51 participants (Actual)Interventional2017-09-25Completed
HALT Progression of Polycystic Kidney Disease Study B[NCT01885559]Phase 3486 participants (Actual)Interventional2006-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Albuminuria

Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Interventionannual percent change (Mean)
ACE-I + Placebo7.5
ACE-I + ARB7.3

Aldosterone

Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up at 8 years (annually assessed)

Interventionannual percent change (Mean)
ACE-I + Placebo-8.8
ACE-I + ARB-10.2

Back or Flank Pain

Report of back or flank pain since the last visit (yes or no) (NCT01885559)
Timeframe: 48 months

Interventionpercentage of participants at 48 months (Number)
ACE-I + Placebo43
ACE-I + ARB46

Cardiovascular Hospitalizations

Cause-specific hospitalizations (cardiovascular) (NCT01885559)
Timeframe: up to 8 years

Interventionevents (Number)
ACE-I + Placebo29
ACE-I + ARB16

Hospitalizations

Hospitalization for any cause (NCT01885559)
Timeframe: up to 8 years

Interventionevents (Number)
ACE-I + Placebo173
ACE-I + ARB136

Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.

(NCT01885559)
Timeframe: Patients followed for 5-8 years with average of 6.5 years follow up

Interventionparticipants (Number)
ACE-I + Placebo116
ACE-I + ARB115

Quality of Life Mental Component Summary

Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Interventionunits on a scale per year (Mean)
ACE-I + Placebo-0.031
ACE-I + ARB-0.079

Quality of Life Physical Component Summary

Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Interventionunits on a scale per year (Mean)
ACE-I + Placebo-0.64
ACE-I + ARB-0.68

Reviews

1 review available for aldosterone and ADPKD

ArticleYear
Hypertension in autosomal dominant polycystic kidney disease.
    Kidney international. Supplement, 1997, Volume: 61

    Topics: Aldosterone; Humans; Hypertension; Polycystic Kidney, Autosomal Dominant; Renal Circulation; Renin-A

1997

Trials

2 trials available for aldosterone and ADPKD

ArticleYear
Angiotensin blockade in late autosomal dominant polycystic kidney disease.
    The New England journal of medicine, 2014, Dec-11, Volume: 371, Issue:24

    Topics: Adolescent; Adult; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co

2014
Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion.
    American journal of physiology. Renal physiology, 2012, Apr-15, Volume: 302, Issue:8

    Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Aquaporin 2; Atrial Natriuretic Factor; Chroni

2012

Other Studies

4 other studies available for aldosterone and ADPKD

ArticleYear
Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study.
    BMC nephrology, 2020, 08-31, Volume: 21, Issue:1

    Topics: Adult; Aged; Aldosterone; Aquaporin 2; Case-Control Studies; Epithelial Sodium Channels; Female; Hum

2020
Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1995, Volume: 10, Issue:8

    Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dihydroxyphenylalanine

1995
Role of renin-angiotensin-aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease.
    Contributions to nephrology, 1997, Volume: 122

    Topics: Aldosterone; Blood Pressure; Catecholamines; Female; Humans; Hypertension; Hypertension, Renal; Male

1997
Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease.
    Kidney international, 1991, Volume: 40, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aldosterone; Atrial Natriuretic Factor; Dietary Proteins

1991